The advisors on GlycoEra’s funding round
Vischer advised GlycoEra in connection with its financing round. The Swiss biotechnology company, closed a USD 130 million Series B funding.
BGPartner advised the lead investor Novo Holdings and new investor LifeArc Ventures on all Swiss legal matters and the negotiations of the operation.
The context
Investor Novo Holdings led the operation, with saw participation from additional new investors LifeArc Ventures, Catalio Capital Management, QIA, MP Healthcare Venture Management, Sixty Degree Capital and Agent Capital. Existing investors, including Sofinnova Partners, 5AM Ventures, Roche Ventures, and Bristol Myers Squibb, also took part to the round.
Max Klement (partner of Novo Holdings), Matthew Hobson (principal of Catalio Capital Management) and Sohaib Mir (partner at LifeArc Ventures) will enter GlycoEra’s board of directors as new members.
The BGPartner team
The BGPartner team included partner Oliver Gnehm (pictured above) and senior associate Victoria Marty, as well as associates Tessa Douma and Anja Spahni.
The Vischer team
The Vischer team featured Matthias Staehelin, Pauline Pfirter, Timothy Woodtli and Natacha Tang (all corporate/M&A).
